Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -40.81
- Piotroski Score 3.00
- Grade Sell
- Symbol (GENE)
- Company Genetic Technologies Limited
- Price $0.77
- Changes Percentage (0%)
- Change -$0
- Day Low $0.77
- Day High $0.79
- Year High $3.75
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/21/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.15
- Trailing P/E Ratio -11.27
- Forward P/E Ratio -11.27
- P/E Growth -11.27
- Net Income $-12,017,219
Income Statement
Quarterly
Annual
Latest News of GENE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
General Motors to cut 1,000 jobs amid EV cost challenges - report
General Motors is reducing its workforce by nearly 1,000 employees worldwide, mainly in the US, to improve operations and address financial issues in its electric vehicle segment. The move aims to cut...
By Yahoo! Finance | 19 hours ago -
Lee Carsley hails England's new generation as he passes reins to Tuchel
Lee Carsley led England to a 5-0 victory over Ireland, fulfilling his interim coaching role. He predicts fierce competition for spots under new coach Thomas Tuchel. The win increased the player pool, ...
By The Guardian | 1 day ago -
Grow Money Like the Rockefeller Family- 5 Ways They Created Generational Wealth
The Rockefellers diversified their wealth from oil to various sectors like real estate and industry, safeguarding it against market volatility. Their philanthropy, strategic financial management, and ...
By Yahoo! Finance | 1 day ago
